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Objective:We aimed to identify characteristics differentiating children undergoing aortic valve replacement by
using mechanical prostheses versus the Ross procedure and to compare survival and the need for aortic valve re-
operation after each procedure.
Methods: From 1983 to 2004, 346 children underwent aortic valve replacement (215 underwent the Ross pro-
cedure and 131 underwent placement of a mechanical prosthesis). Factors associated with procedure choice were
used to construct a propensity score for use as a covariate in regression models to adjust for potential confounding
by indication.
Results: Patients undergoing the Ross procedure were younger, more likely to have a congenital cause, and less
likely to have a rheumatic or connective tissue cause. They had a lower frequency of regurgitation, required more
annular enlargement, and had less concomitant cardiac surgery. Competing-risk analysis showed that 16 years
after aortic valve replacement, 20% of patients had died without subsequent aortic valve replacement, 25% un-
derwent second aortic valve replacement, and 55% remained alive without further replacement. After propensity
adjustment, factors associated with early-phase death included mechanical valves and a nonrheumatic cause. Me-
chanical valves were also associated with constant-phase mortality. Repeated aortic valve replacement was asso-
ciated with the Ross procedure and a rheumatic cause. Both factors were also associated with all-cause cardiac
reoperation. In children receiving mechanical prostheses, younger age and smaller valve size were significant
risk factors for death. Freedom from homograft replacement after the Ross procedure was 82% at 16 years of
follow-up.
Conclusion: Results from this study showed good outcomes and an acceptable complication rate with both valve
choices. Given the significantly increased risk of early and late death in younger children receiving smaller
mechanical valves, the Ross procedure confers survival advantage in this age group at the expense of increased
reoperation risk, especially in patients with a rheumatic cause.Earn CME credits at
http://cme.ctsnetjournals.org
Supplemental material is available online.
Aortic valve disease is common in children and frequently
requires intervention. Congenital aortic valve disease is the
most common pathology in North America and is encoun-
tered in approximately 5% of children with congenital heart
disease.1-3 Although the incidence of rheumatic valve dis-
ease has significantly decreased in the Western world, it re-
mains a major cause of aortic valvulopathy in developing
countries.4 Several developments in interventional cardiol-
ogy allow for early treatment of congenital aortic stenosis,
and recent experience with aortic valve repair techniques
showed encouraging short-term and midterm results in
both congenital and rheumatic valve disease.5-8 Nonethe-
less, in patients with significant valve destruction or after re-
pair or intervention failure, aortic valve replacement (AVR)
is required. AVR in children is associated with several chal-
lenges. Although many replacement options are available,
all alternatives have several limitations.2,3,9-13 AVR with
a mechanical prosthesis and the Ross procedure using
pulmonary autografts are the most commonly used valve
substitutes in children. Mechanical valves in children are
associated with increased frequency of complications, in-
cluding morbidity related to long-term anticoagulation,
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AVR ¼ aortic valve replacement
LVOT ¼ left ventricular outflow tract
PE ¼ parameter estimate
RVOT ¼ right ventricular outflow tract
deterioration of ventricular function caused by the develop-
ment of patient–prosthesis mismatch as the child outgrows
the initial valve, and the need for subsequent prosthetic valve
replacement.2,3,11-13 On the other hand, although the Ross
procedure has growth potential and does not require long-
term anticoagulation, the procedure is technically demand-
ing, and late autograft failure, aortic root dilatation, and
homograft reoperations are common.2-4,14-25
Although several case series exist in the literature re-
porting outcomes after AVR in children, only a few offered
comparisons between different valve options. We aimed to
review a large single-institution experience with AVR in
children and to compare indications and outcomes of chil-
dren undergoing mechanical valve replacement with those
of children undergoing the Ross procedure while adjusting
for potential confounding by indication.
MATERIALS AND METHODS
Inclusion Criteria
From 1983 to 2005, 346 consecutive children under the age of 18 years
required AVR at the King Faisal Specialist Hospital and Research Center in
Riyadh, Saudi Arabia. Those patients received either a bileaflet mechanical
prosthesis (n¼ 131) or underwent the Ross procedure (n¼ 215). In the cur-
rent study we did not include children who had undergone AVRwith ball or
tilting-disc valves because those prostheses are not commonly used any-
more, and therefore their inclusion would not be relevant to current clinical
practice. Patients were identified by using the hospital surgical database.
Clinical, operative, and outcome data were abstracted frommedical records.
Approval of this study was obtained from the research ethics board at our
institution, and requirement for individual consent was waived for this ob-
servational study.
Operative Details
Detailed steps of the surgical intervention will not be discussed in this
section; however, some important information will be briefly listed.4 Mid-
line sternotomy was performed, and standard cardiopulmonary bypass
and myocardial protection techniques were used in all cases. For AVR
with a mechanical prosthesis, the valve was secured to the annulus with mul-
tiple mattressed sutures, with the pledgets placed at the ventricular aspect of
the annulus. For the Ross procedure, the pulmonary autograft was implanted
as a full root, with coronary transfer in all cases. The autograft muscle cuff
was trimmed with sutures placed almost directly at the autograft annulus.
The proximal suture line was performed with running polypropylene su-
tures. The neoaortic annulus was not reinforced in these patients, so as
not to limit growth. In patients with left ventricular outflow tract (LVOT)
obstruction, a modified Ross–Konno technique was used. Part of the septum
was cored out to completely open up the LVOTwithout creating a large ven-
tricular septal defect. In those patients the fibrous annulus of the aortic valve
was often divided, and the cut was partially taken down to the septum. In our
current practice, in patients with a dilated aortic annulus of greater than 29 to
The Journal of Thoracic and C30 mm or with an aortic annulus 2 to 3 mm larger than the pulmonary valve
annulus, the Ross procedure is not considered, and we rarely use any aortic
annulus reduction techniques. The distal suture line was occasionally rein-
forced with Teflon felt in patients with a dilated ascending aorta.
The immediate postoperative results were assessed in all patients in the
operating room by means of transesophageal echocardiographic analysis.
Follow-up
Patients were evaluated clinically and by means of detailed echocardio-
graphic analysis on discharge, 6 weeks after the operation, at 6 months, and
yearly thereafter. Patients with mechanical valves were started on intrave-
nous heparin, maintaining the partial thromboplastin time ratio at between
1.5 and 2 times that of baseline. In addition, all patients received oral sodium
warfarin, aiming to maintain an international normalized ratio within the
range of 2.0 to 3.0. Subsequent to hospital discharge, anticoagulation was
followed by specialized local anticoagulation clinics with established mon-
itoring protocols.
Late outcomes were determined from recent office visits at King Faisal
Specialist Hospital and Research Center or from direct correspondence
with patients’ families. The median follow-up duration was 6.3 years and
was longer for patients who received a mechanical prosthesis (8.3 years;
range, up to 22.9 years) versus those who underwent the Ross procedure
(5.7 years; range, up to 16.4 years; P ¼ .01).
Statistical Analysis
Data are presented as means with standard deviations, medians with min-
imums and maximums, and frequencies, as appropriate. Differences in pa-
tients’ characteristics were calculated by using Student’s t tests with the
Sattertwaite correction and the Fisher’s exact test. Time-dependent out-
comes after AVR were parametrically modeled by using up to 3 phases
of risk (early, constant, and late) as necessary. Competing-risk analysis
was performed to model the probability over time of each of 3 mutually ex-
clusive end points: death, valve reoperation, and alive and free from reoper-
ation. Non–time-dependent outcomes were modeled in logistic regression
models.
To correct for confounding by indication in the procedure assignment
(mechanical valve placement or the Ross procedure), a propensity score
was created, modeling the probability of every patient to be assigned to
the mechanical valve procedure over the Ross procedure based on patient
demographics and medical characteristics. Variable selection was based
on univariate differences between groups (a priori), with backward selec-
tion in the logistic multivariable equation to obtain the final model. A to-
tal of 8 variables were selected (7 of them statistically significant in the
model) for an events-per-variable value of 16.4 (see Table E1). The
model was highly statistically significant (P< .0001) and had excellent
discriminatory power (c-statistic ¼ 0.883). There was no colinearity be-
tween variables, and no interaction criteria were included. There was
very limited overlap between propensity scores in both groups, and there-
fore we used it as a covariate in statistical models. Differences in out-
comes between the patients who had a mechanical valve procedure or
the Ross procedure are reported in the form of hazard/odds ratios for
event if the patient has a mechanical valve procedure instead of the
Ross procedure in both propensity-unadjusted models and propensity-ad-
justed models.
Variables other than aortic valve type, potentially affecting the likelihood
of mortality and reoperation, including sex, year of operation, age at oper-
ation, cause, pathology, previous operations, preoperative catheter interven-
tion, concomitant cardiac operation, and LVOT enlargement, were included
in a multivariable stepwise model (P<.05 to enter) along with aortic valve
type. Backward selection was used to obtain final models for all individual
phases of risk for both outcomes. Finally, procedure-specific variables (me-
chanical valve size, homograft size, homograft preservation [fresh or cryo-
preserved], and homograft type [pulmonary or aortic]) were modeled
individually in each phase of risk for both mortality and reoperation. The
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DTABLE 1. Patients’ characteristics
Cohort (n ¼ 346) Mechanical prosthesis (n ¼ 131 [38%]) Ross procedure (n ¼ 215 [62%]) P value
Sex (male) 260 (75%) 109 (83%) 151 (70%) .007
Mean age at surgical intervention (y) 12.4  4.4 14.0  3.8 11.4  4.6 <.0001
Median year at presentation 1998 (1983–2005) 1996 (1983–2005) 1999 (1991-2004) <.0001
Cause
Rheumatic 201 (58%) 97 (74%) 104 (48%) <.0001
Congenital 116 (34%) 15 (11%) 101 (47%) <.0001
Connective tissue 14 (4%) 12 (9%) 2 (1%) <.0001
Endocarditis 15 (4%) 7 (5%) 8 (4%) .59
Hemodynamic manifestation
Stenosis 44 (13%) 8 (6%) 36 (17%) .005
Regurgitation 224 (65%) 115 (88%) 109 (49%) <.0001
Mixed 78 (22%) 8 (6%) 70 (33%) <.0001
Previous percutaneous intervention 20 (6%) 0 (0%) 20 (9%) <.0001
Previous cardiac operation 97 (28%) 41 (31%) 56 (26%) .33
One previous operation 89 (26%) 36 (27%) 53 (25%)
Two previous operations 8 (2%) 5 (4%) 3 (1%)
Concomitant cardiac operation 147 (42%) 97 (74%) 50 (23%) <.0001
Arch repair 5 (1%) 4 (3%) 1 (<1%) .07
Left ventricular outflow tract enlargement 35 (16%) 3 (2%) 32 (15%) <0.0001clinical relevance of covariates found to influence outcomes was established
through stratification analysis.
All statistical analyses were performed with SAS statistical software ver-
sion 9.1 (SAS Institute, Inc, Cary, NC).
RESULTS
Patient Characteristics
There were 260 (75%) male patients. The mean age at the
time of the index operation was 12.4 4.4 years. The under-
lying valve pathology was rheumatic in 201 (58%) patients,
congenital in 116 (34%) patients, endocarditis in 15 (4%)
patients, and connective tissue disease in 14 (4%) patients.
The hemodynamic aortic valve dysfunction was primarily
regurgitation in 224 (65%) patients, stenosis in 44 (13%)
patients, and mixed in 78 (22%) patients.
Before AVR, 20 (6%) patients had undergone percutane-
ous aortic valve interventions, and 97 (28%) patients had
undergone surgical intervention to address aortic valve le-
sions, other cardiac lesions, or both. Patients’ demographic
and operative characteristics at the time of AVR are listed
in Table 1.
In our series concomitant cardiac surgery was required in
147 (42%) patients, and LVOT enlargement was required in
35 (16%) children, whereas arch repair was performed in 5
(1%) children (Table 1).
The most commonly used mechanical prosthesis was Car-
bomedics (Austin, Tex; n ¼ 123), followed by St Jude (St
Paul, Minn; n ¼ 8). Mean mechanical valve size was 22.1
 2.5 mm. The mean pulmonary homograft size used for re-
construction of the right ventricular outflow tract (RVOT) in
the Ross procedure was 22.7  2.4 mm. Fresh homografts
were used in 52% of patients undergoing the Ross proce-
dure, whereas cryopreserved homografts were used in
48%. Pulmonary homografts were used in 83% of patients
undergoing the Ross procedure, whereas 17% received aor-
tic homografts. Homografts were not generally matched for
the blood group of the patients.
Factors Associatedwith the Choice of Ross Procedure
Versus Mechanical AVR
The Ross procedure was introduced at our institution in
1990, and since then, it has become the most common
procedure performed for AVR in children. AVR with
a mechanical prosthesis has been used at our institution
since the beginning of this study period in 1983. Female
patients were found to be more likely to undergo a Ross
procedure than to receive a mechanical prosthesis. Chil-
dren who underwent the Ross procedure were younger,
presented in more recent years, and were more likely to
have a congenital cause, preoperative stenosis, or mixed
aortic disease. Patients who had a mechanical valve placed
were older, presented in earlier years, and were more
likely to have a rheumatic or connective tissue cause
and preoperative aortic regurgitation and to have under-
gone concomitant cardiac surgery. Arch repair was some-
what more likely in the mechanical valve group, whereas
concomitant LVOT enlargement was more likely in the
Ross procedure group. In patients undergoing the Ross
procedure, concomitant surgical intervention was mainly
mitral valve repair (n ¼ 39) in addition to a few cases
of ventricular septal defect closure, coronary artery bypass
grafting, and pulmonary angioplasty. On the other hand,
concomitant surgical intervention in patients receiving
a mechanical aortic prosthesis included mitral valve re-
placement (n ¼ 71), mitral valve repair (n ¼ 7), tricuspid
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DTABLE 2. Incremental risk factors for time-related transition from initial AVR to either death or a second AVR
Unadjusted Propensity adjusted
Estimate ± SE P value Estimate ± SE P value
Death without subsequent AVR: Early phase
Valve type (mechanical vs Ross) 2.05  0.57 .0004 2.71  0.70 .0001
Cause other than rheumatic 1.75  0.77 .03 2.10  0.69 .003
Younger age at surgical intervention 0.12  0.05 .03
Death without subsequent AVR: Constant phase
Valve type (mechanical vs Ross) 1.60  0.58 .007 1.72  0.65 .009
Concomitant operations 2.74  1.01 .007
Survival to a subsequent AVR: Late phase
Valve type (Ross vs mechanical) 2.72  0.48 <.0001 2.47  0.47 <.0001
Rheumatic cause 1.92  0.62 .002 2.09  0.61 .0006
Concomitant cardiac surgery 0.91  0.38 .02
AVR, Aortic valve replacement; SE, standard error.Cvalve repair (n ¼ 16), tricuspid valve replacement (n ¼
1), aortic root replacement (n ¼ 8), and right ventricle–
pulmonary artery conduit change (n ¼ 5). The frequency
of previous cardiac operation was similar between groups
(Table 1).
Competing Risk Analysis for Death or Subsequent
Prosthesis Replacement After Initial AVR
After the 346 initial AVRs, 36 patients had their valves
subsequently replaced, and 32 patients died without a further
AVR, including 13 (3.7%) operative deaths. The hazard
function for time-related transition to a second AVR was
characterized by the presence of a late hazard phase that
steadily increases as years since surgical intervention pro-
gressed (see Figure E1). The hazard function for time-related
transition to death without a second AVR was characterized
by an early hazard phase with a high level of risk in the im-
mediate postoperative period and a constant hazard phase in-
dicating a continuous attrition rate over time (see Figure E2).
The competing risks for the 2 events showed that at 16 years
after AVR, approximately 20% of patients have died, 25%
have undergone a second aortic valve reoperation, and 55%
are alive and free from aortic reoperation (see Figure E3).
Factors Associated with Mortality
There were 13 (3.7%) operative deaths: 5 (2.3%) in
patients undergoing the Ross procedure and 8 (6.1%) in
patients receiving a mechanical prosthesis. Furthermore,
there were 19 additional deaths during the follow-up dura-
tion; all were of patients who received a mechanical prosthe-
sis. Factors associated with higher risk of death after initial
AVR were sought, and results are shown in Table 2.
Unadjusted risk analysis showed that variables linked to
early-phase mortality included the placement of a mechani-
cal valve, younger age at the time of valve replacement, and
an underlying cause other than rheumatic. In addition to me-
chanical valves, concomitant cardiac surgery was related to
higher constant-phase mortality risk.
An effect of younger age on increased early-phase mortal-
ity was seen in children undergoing AVR with a mechanical
prosthesis but neutralized in those undergoing the Ross
procedure, as seen in the predictive model shown in
Figure 1. Moreover, smaller mechanical valve prosthesis
size, strongly linked to age at initial AVR, was associated
with constant-phase mortality (hazard ratio, 1.5/mm; 95%
confidence interval, 1.2–1.9; P ¼ .0007; see Figure E4).
In propensity-adjusted analysis placement of amechanical
valve was associated with both early-phase (parameter esti-
mate [PE], 2.7  0.7; P ¼ .0001) and constant-phase (PE,
1.7  0.7; P ¼ .009) mortality risk (Figure 2). Underlying
cause other than rheumatic remained a significant risk factor
for early-phase mortality after propensity adjustment (PE,
2.1  0.7; P ¼ .003).
Factors Associated with Aortic Valve Reoperation
During follow-up, there were 36 aortic valve reoperations:
8 in patients who have received a mechanical prosthesis and
28 in patients who had a Ross procedure. Factors associated
with the time-related risk of subsequent replacement after
initial AVR were sought, and results are shown in Table 2.
Unadjusted risk analysis showed that variables linked to
aortic valve reoperation included undergoing theRoss proce-
dure, underlying rheumatic cause, and concomitant cardiac
surgery. In addition, placement of a small prosthesis was as-
sociated with increased risk for aortic valve reoperation in
children who received a mechanical prosthesis (hazard ratio,
1.5/mm; 95% confidence interval, 1.2–3.9; P ¼ .05).
In propensity-adjusted analysis the Ross procedure was
strongly linked with late-phase reoperation risk (PE, 2.5 
0.5; P< .0001), as shown in Figure 3. Additionally, under-
lying rheumatic pathology was an important risk factor for
late subsequent aortic valve reoperation (PE, 2.1  0.6;
P ¼ .0006; see Figure E5). This effect was more apparent
in patients who underwent a Ross operation compared
with those who received a mechanical prosthesis (Figure 4).
We analyzed whether the hemodynamic manifestation
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operation, especially in patients with a rheumatic cause
undergoing the Ross procedure. The presence of pure regur-
gitation, stenosis, or mixed disease did not significantly
influence subsequent reoperation (see Figure E6).
Factors Associated with Any Cardiac Reoperation
A total of 68 patients (49 undergoing the Ross procedure
and 19 receiving a mechanical prosthesis) had a cardiac
reoperation, including but not limited to a second AVR. At
16 years after AVR, about 40% of patients have undergone
additional cardiac operations. In competing-risk models fac-
tors associated with any cardiac reoperation were the same
as those associated with increased risk of survival to subse-
quent AVR (see Figure E7), with the exception of LVOT en-
largement (PE, 1.55  0.43; P ¼ .0004) at the initial
intervention, which was found to increase time-related risk
of surviving to cardiac reoperation.
Functional Status and Additional Late Morbidity
At the most recent follow-up, the majority of survivors
(91%) had normal clinical exercise ability and were in
New York Heart Association functional class I. There was
no significant difference in the number of patients in New
York Heart Association class greater than 1 between those
FIGURE 2. Propensity-adjusted effect of initial aortic valve replacement
type (Ross procedure or mechanical prosthesis) on survival without re-
peated aortic valve reoperation. The solid lines represent parametric point
estimates, and the dashed lines enclose the 95% confidence interval.
FIGURE 3. Propensity-adjusted effect of initial aortic valve replacement
type (Ross procedure or mechanical prosthesis) on survival to repeated aor-
tic valve reoperation. The solid lines represent parametric point estimates,
and the dashed lines enclose the 95% confidence interval.
FIGURE 4. Propensity-adjusted effect of initial aortic valve replacement
type (Ross procedure or mechanical prosthesis) and disease cause on sur-
vival to repeated aortic valve reoperation. The solid lines represent paramet-
ric point estimates. M-NR, Mechanical nonrheumatic; M-R, mechanical
rheumatic; R-NR, Ross nonrheumatic; R-R, Ross rheumatic.
FIGURE 1. Survival without repeated aortic valve reoperation stratified by
age in patients undergoing aortic valve replacement with the Ross procedure
versus placement of a mechanical prosthesis. The effect of younger age on
early-phase mortality was neutralized for patients undergoing the Ross pro-
cedure because the 2 lines almost overlap, whereas the effect remained sig-
nificant for those undergoing aortic valve replacement with a mechanical
prosthesis. Solid lines represent parametric point estimates.
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recipients (13%).
For patients who underwent the Ross procedure, 16-year
freedom from homograft reoperation was 82% (Figure E8).
Homograft reoperation was not influenced by the type of
conduit.
Although there was an apparent increase in valve-related
morbidity in children who received mechanical prostheses,
that difference did not reach statistical significance because
of the limited numbers of documented valve-related morbid
events. All anticoagulation-related and thromboembolic
complications were obviously in patients who received a
mechanical prosthesis: bleeding (n ¼ 3), valve thrombosis
(n ¼ 2), and embolization (n ¼ 2). There were 3 episodes
of endocarditis, all requiring reoperation and aortic valve
rereplacement: 2 were after the Ross procedure and 1 was
after mechanical valve replacement.
DISCUSSION
Our study reports a single institution’s experience with
AVR by using bileaflet mechanical valves or the Ross pro-
cedure in 346 children. Competing-risks analysis was cho-
sen because these patients were simultaneously at risk for
2 mutually exclusive events: death and reoperation with
prosthesis replacement. Conventional time-related analyses
consider individual events, such as death or reoperation, ei-
ther in isolation or as a combined end point. Although use-
ful, they do not address the question of how often an event
might occur in the absence of other events for which a patient
is at simultaneous risk.
Factors Associatedwith the Choice of Ross Procedure
Versus Mechanical Valve
The primary objective of this study was to determine the
effect of AVR choice on survival and reoperation in children
with aortic valve disease. However, examination of the data
revealed important differences between these 2 patient
groups. Patients undergoing replacement with a mechanical
valve were more likely to have associated cardiac diseases
requiring concomitant cardiac surgery and more likely to
have a rheumatic or connective tissue cause. Children under-
going the Ross procedure, on the other hand, were younger,
more likely to have congenital valve disease, or more likely
to require enlargement of the LVOT. Many of those vari-
ables can influence mortality and reoperation risk. The dis-
parity of characteristics of patients undergoing the Ross
procedure versus mechanical valve placement decreases
the usefulness of unadjusted comparison. Propensity-ad-
justed analysis allows fair comparison to determine the ef-
fect of procedure type on short- and long-term outcomes.
Mortality Risk
Several variables were found to significantly increase the
risk of mortality. Mechanical valves were associated with
The Journal of Thoracic and Cearly- and constant- phase mortality. This is in line with
other reports indicating an operative survival advantage for
the Ross procedure over mechanical valve placement.2,3
Despite surgical complexity, the Ross procedure is safe in
experienced hands. In our series mortality was 2.3%, which
is similar to the data from the International Registry for the
Ross Procedure (2.5%) compared with 6.1% for mechani-
cal valves.
Despite high association with concomitant cardiac and
multivalvular surgery, early mortality after AVR for a rheu-
matic cause was less than 1% compared with 7% for other
causes.
Younger age was found to be significant in unadjusted
analysis. The effect of age was neutralized in patients under-
going the Ross procedure but remained important in the me-
chanical prosthesis group. Operative mortality for patients
younger than 5 years in our study was 50% for mechanical
valves, whereas it was less than 4% for the Ross procedure.
Additionally, the need for LVOT enlargement (Ross–Konno
procedure) was not associated with a significant increase in
operative mortality (6%). In children less than 2 years of
age, our experience with the Ross procedure remains limited
to 10 patients with 1 operative death.
More importantly, survival was stable for the Ross proce-
dure, with no late mortality compared with 19 additional car-
diac-related deaths in the mechanical prosthesis group.
Many of those deaths were sudden in nature, highlighting
the delicate problem of compliance with the anticoagulation
regimen and its implication on patients’ lifestyle that is espe-
cially difficult to control in children and young adults. De-
spite having well-established anticoagulation protocols and
follow-up within specialized anticoagulation clinics in Saudi
Arabia, educational and social factors might influence com-
pliance with the anticoagulation protocol, and therefore
these late outcomes might differ in the Western world com-
pared with those seen in other countries. On the other hand,
several other publications from North America and Europe
similarly reveal a steady attrition rate in children who have
received mechanical prostheses, indicating that this anticoa-
gulation problem in children remains true in developed
countries.2,3,11-13
Reoperation Risk
The Ross procedure was a risk factor for aortic valve re-
operation and overall cardiac reoperations. There were 28
children thus far who have required AVR at a median of
2.8 years after the Ross procedure. Twenty-seven of those
patients who had a rheumatic cause, and 26 had pure aortic
regurgitation preoperatively. We have previously reported
higher autograft reoperation rates in rheumatic patients com-
pared with those with other causes.4,5 The mode of failure in
our series included aortic root dilatation and cusp elongation
and prolapse in 46%, recurrent rheumatic disease in 25%,
an inflammatory process that is likely recurrent rheumatic
ardiovascular Surgery c Volume 137, Number 2 367
Congenital Heart Disease Alsoufi et al
C
H
Ddisease in 18%, aneurysm formation in 7%, and endocardi-
tis in 4%. We have previously identified risk factors for au-
tograft failure, and those include active rheumatic heart
disease, concomitant severe rheumatic mitral regurgitation,
pure regurgitation with severe dilatation of the LVOT
greater than 29 mm, or discrepancy between the LVOT
and RVOT of greater than 2 to 3 mm in favor of the
LVOT.5 By adhering to new selection criteria and avoiding
patients with the above listed risk factors and by adapting
surgical modifications, such as careful trimming of the mus-
cle rim under the autograft and suturing close to the annulus
because this muscle rim might dilate and contribute to future
failure and occasional reinforcement of the dilated sinotub-
ular junction, we expect that we will be encountering less in-
stances of autograft failures in patients with a rheumatic
cause. Since adopting those changes in 1999, only 2 patients
with a rheumatic cause required autograft change. Despite
a relatively shorter follow-up period, this finding is encour-
aging considering that most failures were previously evident
in the first 2 to 3 years after surgical intervention.
Concerns of pulmonary autograft dilatation have stimu-
lated recent developments in surgical strategies to address
late root dilatation. Most recently, inspired by a technique
that was previously used in mitral valve replacement with
a pulmonary autograft, Slater and colleagues26 described
a modified pulmonary autograft implantation procedure in
which the pulmonary autograft was encased in a Dacron
tube to prevent future dilatation. They suggested that this
procedure can be applied to fully grown children and young
adults and reported excellent short-term results with respect
to autograft valve function and lack of dilatation of the annu-
lus or sinotubular junction.26
Implications on Clinical Practice Internationally
Our patient population is different from that in published
reports from the Western world because of the high percent-
age of rheumatic valve disease. Nonetheless, important in-
formation can be obtained from our analysis to help in the
difficult decision of AVR strategy in children.
In theWestern world the prevalence of rheumatic valve dis-
ease is much less, and the majority of patients undergoing
AVR have underlying congenital pathology. Children with
congenital aortic valve diseasemight require surgical interven-
tion at an early age and have small annuluses requiring LVOT
enlargement. Based on our analysis, the Ross procedure con-
fers survival advantage in this population because mortality
risk is low in experienced centers, and some risk factors for
mortality are neutralized in this population comparedwithme-
chanical valves, in which younger age and smaller prostheses
remain important risk factors for early and late death. Simi-
larly, freedom from autograft reoperation in patients without
a rheumatic cause after the Ross procedure was high, and
therefore the projected autograft longevity in Western series
is longer. Into the bargain, mortality risk during valve reoper-
368 The Journal of Thoracic and Cardiovascular Sation in the current era is low, and valve-preserving root re-
placement techniques in cases associated with root dilatation
and autograft regurgitation have been described, which might
increase valve longevity despite aortic wall reintervention.27
RVOT reoperation remains a concern in patients after the
Ross procedure. Again, mortality risk during RVOT reinter-
vention is low, and recent advances with percutaneous pul-
monary valve replacement might allow cardiologists to
address this problem without surgical intervention.28 The
immediate and short-term results of percutaneous pulmo-
nary valve implantation are very encouraging, and these pro-
cedures were recently performed at our institution in patients
after the Ross procedure with excellent immediate results.27
The perceived additional advantages of the Ross procedure
in children, such as improved survival, the avoidance of anti-
coagulation-related morbidity, the ability to match somatic
growth, and the concern of anticoagulation during preg-
nancy in female patients, might encourage surgeons to con-
sider the Ross procedure in children as the aortic valve
substitute of choice despite RVOT reintervention incidence.
Study Limitations
The present report is a retrospective analysis of patients
from a single institution with diverse anatomy who under-
went an operation during a 22-year time span. Despite the
use of a comprehensive set of variables in all analyses, un-
measured covariates might have contributed to disparate
outcomes in the recipient populations. In addition, this study
addresses survival and reoperation after AVR in children but
does not examine the effect of prosthesis type on cardiac he-
modynamics, left ventricular recovery, and ventricular and
aortic root dimensions.
CONCLUSIONS
The study suggests excellent functional status and accept-
able complication rates with both valve choices. Given a sig-
nificantly increased risk of early and late death in younger
children receiving smaller mechanical valves, the Ross pro-
cedure confers survival advantages in this age group at the
expense of increased reoperation risk, especially in patients
with a rheumatic cause.
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The Journal of Thoracic and CDiscussion
Dr Vaughn A. Starnes (Los Angeles, Calif). Dr Alsoufi and col-
leagues have performed a retrospective analysis on 346 children
receiving aortic valves, either mechanical prostheses or the Ross
procedure, over a 21-year period. The operative experience was
from 1983 to 2004. In an attempt to neutralize confounding in
the selection of a prosthesis, a propensity-adjustment comparison
was performed. In summary, we have heard that the Ross procedure
confers survival advantage over the mechanical cohort because of
the higher operative mortality and the continuous attrition in the
late follow-up period in the mechanical group.
I agree with the conclusions of the article, and I also support the
use of the Ross procedure over the mechanical valve in children.
The reason mechanical valves fail in children include lack of
growth of the prosthesis, leading to a patient–prosthesis mismatch;
valve failure caused by pannus formation; poor compliance with
taking medications (warfarin), particularly in adolescents; and, in
women, the issue of pregnancy and warfarin. I have 3 questions.
Your analysis using a propensity-adjusted comparison was per-
formed to neutralize, as best you could, confounding variables that
overlap, but we have 1 curious nonoverlapping variable that I
would like to ask you about: the time of the study. From 1983 to
1990, you used mechanical valves alone, according to your article.
Would it not have been better to start this study from 1990 onward
when you had mechanical and Ross procedures available in your
facility? Could you explain why you chose the earlier time period?
Dr Alsoufi. Thank you, Dr Starnes. In a retrospective review of
outcomes in 2 diverse groups of patients, it might be difficult to per-
form a fair comparison. Propensity score analysis remains the best
analysis method that we can use in this situation. However, there
might have been several covariates that we have not identified or
used; those unmeasured covariates could have contributed to dispa-
rate outcomes in our patients.
Although the surgical era was different between the 2 groups of
patients, as you havementioned, it was not identified as a significant
factor for mortality in our risk analysis. We included patients before
1991 to increase the power of our study by adding more patients
and having longer follow-up. Moreover, surgical era was one of
the variables that we have used to create our propensity score.
Dr Starnes. Well, I have 2 interrelated questions, and I think it
pertains to looking at these 2 time periods. It appears from your ar-
ticle that a lot of mechanical valves were used early on, and then
you had a tendency in your facility to use Ross procedures later.
Therefore I have 2 questions based on that background.
Rheumatic heart disease comprised the largest cohort of patients
in your series and represented a risk factor for reoperation. Patients
with rheumatic heart disease who underwent a Ross procedure were
at even higher risk for reoperation. Do you currently recommend
a mechanical prosthesis in these children, or are you currently do-
ing Ross procedures?
Dr Alsoufi. Initially, after adopting the Ross procedure at our in-
stitution in 1991, it was offered to all patients. Later, our group was
one of the first to report an increased risk of failure after the Ross
procedure in patients with rheumatic valve disease. We have iden-
tified several risk factors for increased failure rate. Those included
patients who had active rheumatic fever at the time of AVR, pa-
tients who had pure aortic insufficiency and a dilated annulus larger
than 30 mm, and patients who had an aortic annulus 3 mm or more
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Dlarger than that of the pulmonary valve. In those patients we do not
offer the Ross procedure anymore. In addition, we have adopted
some technical modifications, most importantly by trimming the
muscle rim underneath the autograft with sutures almost going to
the annulus level, because we had identified that this muscle often
dilated and contributed to late failure. Because we have changed
our selection criteria and adapted those modifications in 1999, we
have had 2 failures only in patients with rheumatic disease under-
going the Ross procedure. Although the follow-up is not very
long, this is an encouraging finding given that most of the failures
in the past were evident within the first 3 years after AVR.
Dr Starnes. For my final question, given the high operative
mortality in children receiving mechanical valves less than 5 years
of age, almost 50%, do you currently use the Ross procedure exclu-
sively in this age group?
Dr Alsoufi. Yes.
Dr Starnes. Again, I would like to thank you for providing me
the manuscript, which is excellently written, and thank the Associ-
ation for the privilege of the discussion.
Dr David J. Cohen (San Antonio, Tex). I had the privilege of
visiting your hospital while deployed during Operation Desert Storm,
and it was my impression at that time that many of your patients came
from many different countries and also from small villages, where
long-term follow-up for anticoagulation and for subacute bacterial en-
docarditis prophylaxiswould be impossible to follow. I amwondering
if much of the late attrition rate in your patients receiving mechanical
valves is related to this issue and whether this would be the same if
these patients had been treated, say, in the United States or in Europe?
Dr Alsoufi. The majority of our patients were from Saudi Ara-
bia, even though they came from all over the country. Although an-
ticoagulation follow-up is not done at our hospital but rather at local
centers, all those centers have anticoagulation clinics with well-es-
tablished anticoagulation protocols. The issue of compliance with
anticoagulation in children is definitely a major problem. Compli-
ance might be better in the Western world than in other developing
countries because of many social, educational, and logistic factors.
However, multiple other published series from Europe and the
United States showed similar findings, continuous attrition with
mechanical valves and high anticoagulation-related morbidity, in-
dicating that anticoagulation control in children remains a problem,
even in the Western world.
Dr Themistokles P. Chamogeorgakis (Athens, Greece). As far
as neonates, this is a difficult subgroup to manage. Do you have any
information or how many neonatal Ross procedures you did or
Ross–Konno combinations?
Dr Alsoufi. Our experience with the Ross procedure in infants is
limited to 10 patients only, with 1 (10%) death. Therefore despite our
large series, the number of infants and neonates is smaller than that
seen in other published reports. For the Ross–Konno procedure, we
have a large institutional experience, 39 patients with 2 (6%) deaths.
Dr James H. Oury (Rapid City, SD). I commend you on an ex-
cellent series, and it fills a gap, at least in the Ross registry data that
we have, including your data, of what happens to these children
long-term. Therefore my question is purely from a hemodynamic
status, and it is based on the fact that children, by their nature, ex-
ercise, sometimes wildly. To get some handle on this, we took
about 15 patients from our series and compared them. These
were athletes. We compared the athletes undergoing the Ross pro-
cedure with a group of so-called normal triathletes, and I can tell
you that at extreme exercise in young adults, the results are super-
imposable. Therefore my question to you is this: Given this unique
series, have you had the opportunity of comparing the patients un-
dergoing the Ross procedure with those receiving mechanical
valves in terms of their hemodynamic potential and looking at these
2 series as the kids grew older?
Dr Carlos J. Troconis (Caracas, Venezuela). From experiences
in undeveloped countries, where noncompliance on conventional
anticoagulation treatment is almost the rule and complications
from anticoagulation issues were frequently less likely to be found
in these population groups, other published series from Europe or
from the United States have advocated, in a prospective, non-
randomized, longitudinal multicenter trial, to test the hypothesis
that selected patients after AVR with an already established com-
mercial valve can be maintained safely with low-dose aspirin
only or with aspirin/clopidogrel.
Although we know that more patients and longer follow-up are
required to draw valid conclusions, I particularly think that this an-
ticoagulation modality, when applied to AVR, could be extended to
kids. Do you have any observations about that?
Dr Alsoufi. I will answer the last question first. All our patients
were anticoagulated with warfarin, with a recommended interna-
tional normalized ratio range between 2 and 3. Sometimes we added
aspirin for patients in whom maintaining international normalized
ratio within the therapeutic range was difficult, but we did not leave
them without anticoagulation. Although there are current trials to
maintain adult patients who have received a certain mechanical
valve while receiving clopidogrel and aspirin only, this is not yet
the standard of care, and that valve was not used in our patients.
To answer the first question, although the majority of our pa-
tients were asymptomatic, exercise data were largely unavailable.
We are currently collecting serial echocardiograms after AVR in
children with the purpose of examining trajectories for left ventric-
ular mass regression, recovery of ventricular dilatation, systolic
function, and progression of aortic annulus and root diameters,
and we hope to share this information with you in future meetings.
We do not have current plans to compare exercise performance be-
tween children who have undergone a Ross procedure versus those
who have received a mechanical valve. Although this has been pre-
viously done in adults, no data exist in children, and that will be an
excellent study to perform.370 The Journal of Thoracic and Cardiovascular Surgery c February 2009
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DFIGURE E1. Parametric model for overall survival for the entire cohort is
composed of 2 phases of risks: an early phase with a high level of risk in the
immediate postoperative period and a constant phase indicating a low but
increasing risk of attrition over time. The solid lines represent parametric
point estimates, and the dashed lines enclose the 95% confidence interval.
Circles represent nonparametric estimates.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 370.e1
Congenital Heart Disease Alsoufi et alFIGURE E2. Parametric model for survival to aortic valve reoperation for
the entire cohort is composed of a late hazard phase that steadily increases as
years since surgical intervention progressed. The solid lines represent para-
metric point estimates, and the dashed lines enclose the 95% confidence in-
terval. Circles represent nonparametric estimates.
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DFIGURE E3. Competing risk depiction of outcomes after initial aortic
valve replacement. At the time of initial aortic valve replacement, all pa-
tients are alive and free from subsequent aortic valve replacement. Aortic
valve replacement is associated with an early risk of operative mortality
(4%), followed by a constant attrition rate. The time-related risk of aortic
valve reoperation steadily increases as time from surgical intervention aug-
ments. At 10 years after the index procedure, approximately 10% of patients
have died without subsequent aortic valve replacement, 15% have under-
gone a second aortic valve replacement, and 75% are alive and free from
subsequent aortic valve replacement. The solid lines represent parametric
point estimates.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 370.e3
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DFIGURE E4. Parametric model in patients with mechanical valves for
mortality without subsequent aortic valve replacement by initial mechanical
valve size. The solid lines represent parametric point estimates.370.e4 The Journal of Thoracic and Cardiovascular Surgery c February 2009
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DFIGURE E5. Parametric model for survival to subsequent aortic valve re-
operation underlying pathology. The solid lines represent parametric point
estimates. CTD, connective tissue disease.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 370.e5
Congenital Heart Disease Alsoufi et al
C
H
D FIGURE E6. Parametric model in patients with a rheumatologic cause
who underwent the Ross procedure for survival to subsequent aortic valve
reoperation. The solid lines represent parametric point estimates, and the
dashed lines enclose the 95% confidence interval.370.e6 The Journal of Thoracic and Cardiovascular Surgery c February 2009
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DFIGUREE7. Propensity -adjusted effect of initial aortic valve replacement
type (Ross procedure or mechanical prosthesis) on survival to any cardiac
reoperation. The solid lines represent parametric point estimates, and the
dashed lines enclose the 95% confidence interval.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 370.e7
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D FIGURE E8. Parametric model for survival to homograft replacement for
patients who underwent the Ross procedure. The solid lines represent para-
metric point estimates, and the dashed lines enclose the 95% confidence in-
terval. Circles represent nonparametric estimates.370.e8 The Journal of Thoracic and Cardiovascular Surgery c February 2009
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DTABLE E1. Factors included in the propensity score
Estimate ± SE P value
Year 0.112  0.035 .003
Sex (male) 0.300  0.190 .12
Age at surgical intervention 0.128  0.045 .005
Rheumatic 1.713  0.540 .003
Congenital 2.153  0.644 .001
Regurgitation 1.229  0.445 .006
Additional procedure 2.086  0.311 <.0001
Previous operations 1.430  0.365 <.0001
SE, Standard error.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 370.e9
